The pharmaceutical company has requested an extension to publish its financial results for the year ended 30 June 2025 due to an ongoing legal dispute regarding the appointment of additional independent directors.
The pharmaceutical company has partnered to launch a generic version of a lifesaving cystic fibrosis treatment at a significantly lower price than the branded product.
The pharmaceutical company provides an update on the ongoing High Court hearing regarding the BSEC's proposed appointment of additional independent directors to the Board.
The pharmaceutical company has requested an extension to publish its Q3 financial results due to an ongoing legal matter regarding the appointment of additional independent directors.
The pharmaceutical company denies allegations of corruption in Covid-19 vaccine procurement and provides an update on a regulatory order regarding its board of directors.
The pharmaceutical company faces regulatory uncertainty over the proposed appointment of additional independent directors to its board, with a court decision expected by mid-March.
The pharmaceutical company has announced a change in its Board of Directors, with a new Non-Executive Director nominated by a major shareholder.
The generic drug manufacturer reported an 8.8% increase in net sales and a 17.5% rise in profit after tax for the half-year. Export sales surged by 31.6%, with expansion into new markets.
Pharmaceutical company faces potential Board shake-up as regulator seeks to appoint new directors
The pharmaceutical company held its Annual General Meeting, approving a 40% cash dividend and a name change, but the announcement contains no major updates.